Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[99mTc]Tc-G3-(G3S)3C SPECT Imaging in Breast Cancer
NCT05923268Phase 1Completed
- Sponsor
- Tomsk National Research Medical Centre of the Russian Academy of Sciences
- Start
- Jun 2023
- Primary completion
- Jun 2024
- Modality
- Carrier/Scaffold Proteins
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of [99mTc]Tc-(HE)3-G3 in breast cancer, sponsored by Tomsk National Research Medical Centre of the Russian Academy of Sciences. Primary endpoints: Gamma camera-based whole-body [99mTc]Tc-G3-(G3S)3C uptake value at 6 hours, SPECT-based [99mTc]Tc-G3-(G3S)3C uptake value in tumor lesions at 6 hours and 2 more. Started Jun 2023; status: completed.
02
Drugs
[99mTc]Tc-(HE)3-G3
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05923268.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05923268.